Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.71 USD
-0.01 (-0.58%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $1.70 -0.01 (-0.58%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.71 USD
-0.01 (-0.58%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $1.70 -0.01 (-0.58%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Zacks News
Fortress Biotech (FBIO) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 44.70% and 0.49%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -4.17% and 29.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of 6.45% and 221%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here Is Why Bargain Hunters Would Love Fast-paced Mover Fortress Biotech (FBIO)
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies (AQB) delivered earnings and revenue surprises of -7.75% and 4.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 26.09% and 40.95%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Aveanna Healthcare (AVAH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aveanna (AVAH) delivered earnings and revenue surprises of 40% and 1.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 20% and 1.37%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech (FBIO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -10.53% and 23.98%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Fortress Biotech (FBIO) Q1 Earnings Expected to Decline
by Zacks Equity Research
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of -2.04% and 64.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 7.41% and 13.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Bellus Health (BLU) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Bellus (BLU) delivered earnings and revenue surprises of -11.11% and 60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Twist Bioscience (TWST) Surges 16.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Twist Bioscience (TWST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 2.13% and 5.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 20% and 23.18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech (FBIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -20% and 17.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of -18.75% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Fortress Biotech (FBIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -6.32% and 70.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -7.27% and 37.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 35.71% and 19.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -6.33% and 48.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech (FBIO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -225.00% and 14.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?